Loading...
Newsroom 2018-04-11T09:57:49+00:00

In the News

April 9, 2018

New: Inflammatix: a 2018 World Changing Ideas Award Finalist!

Link to story

March 15, 2018

Read Immune Responses to See Infections

Link to story

March 12, 2018

Inflammatix announced findings from a new study published in Nature Communications

Link to story

March 9, 2018

Spotlight: Interrogating the Immune System for Diagnosing Infection

Link to story

February 22, 2018

Informing Infection. Measuring gene expression patterns to diagnose and inform treatment decisions.

Link to story (PDF)

February 21, 2018

Sepsis severity may be discernible, new study suggests

Link to story

February 15, 2018

Study: Inflammatix’ HostDx sepsis test can aid in diagnosis, risk of sepsis

Link to story

January 17, 2018

Inflammatix Immune Response Tests could enable antibiotic decisions in one hour

Link to story (PDF)

December 19, 2017

 How a young Peninsula company snagged a onetime Roche exec to battle sepsis

Link to story

September 28, 2017

 Diagnosis: Frontiers in blood testing
Technological advances are creating an explosion in possibilities for the blood-based diagnosis of brain injuries, infections and cancers.

Link to story

June 12, 2017

Wanted: More Data, the Dirtier the Better
Embracing messy data as a way to capture the messiness of disease

Link to story

May 24, 2017 

Stanford Spinout Inflammatix Developing Sepsis Diagnostic Based on Host Immune Response

Link to story (PDF)

October 24, 2016

Researchers at the Stanford University School of Medicine Develop Cutting-Edge Test to Identify Whether an Infection is Bacterial or Viral

Link to story

July 7, 2016

A Blood Test to Determine when Antibiotics are Warranted

Link to story

July 6, 2016

For someone with an infectious disease, the ability to distinguish between a viral and a bacterial cause would be game-changing

Link to story

July 6, 2016

Simple blood test distinguishes between viral, bacterial infections

Link to story

June 6, 2016

Do You Really Need Antibiotics? This Test Can Tell.

Link to story

July 28, 2015

Interview with Tim Sweeney, MD, PhD, Co-Founder of Inflammatix

Link to Interview (begins @ 19:40)

Press Releases

April 10, 2018 – Inflammatix Named a Finalist in Fast Company’s 2018 World Changing Ideas Awards for Its Novel HostDx Tests 2018-04-10T09:55:32+00:00

Burlingame, Calif., April 10, 2018  — Inflammatix announced today that it has been named a finalist in Fast Company’s 2018 World Changing Ideas Awards for its novel HostDx™ tests, which read the immune system to tackle the global health problems of antibiotic resistance and sepsis. The annual award honors businesses, policies, projects and concepts that offer innovative solutions to the issues facing humanity. Finalists and winners will be highlighted in the May issue of the print magazine, which hits newsstands on April 17.

“We are deeply honored to receive this recognition from Fast Company, which is recognized worldwide as an authority on innovation,” said Tim Sweeney, M.D., Ph.D., co-founder and chief executive officer of Inflammatix. “This recognition emphasizes our commitment to harnessing the power of the immune system to improve patient care and resolve major clinical and public health challenges.”

Inflammatix is working with clinical diagnostics instrument partners to commercialize its HostDx tests, which will initially target acute bacterial and viral infections and sepsis. Rather than look for specific pathogens or biomarkers of disease, which lack accuracy and speed, the HostDx tests measure the genomic “fingerprint” of the host response to disease and apply proprietary machine learning algorithms to accurately identify whether an infection is bacterial or viral – and thus whether antibiotics are required – and to determine if the patient is likely to have or develop sepsis.

About the World Changing Ideas Awards

World Changing Ideas is one ofFast Company’s major annual awards programs and is focused on social good, seeking to elevate finished products and brave concepts that make the world better. A panel of judges from across sectors chooses winners and finalists based on feasibility and the potential for impact. With a goal of awarding ingenuity and fostering innovation, Fast Companydraws attention to ideas with great potential and helps them expand their reach to inspire more people to start work on solving the problems that affect us all.

Now in its second year, the World Changing Ideas Awards showcases 12 winners and more than 200 finalists. A panel of eminent judges selected winners from a pool of more than 1,300 entries in 12 categories, with entries from across the globe.

About Inflammatix

Inflammatix is a molecular diagnostics company that is developing rapid tests that read the immune system, enabling improved patient care and reducing major public health burdens. The company’s initial focus is on acute bacterial and viral infections, and sepsis, where its HostDx™ tests will allow physicians to quickly get the right treatments to the right patients, reducing morbidity and mortality, health system costs, and antibiotic resistance.While current tests diagnose infections by “finding the bug” – an approach that misses the 70% of infections that never enter the bloodstream – Inflammatix evaluates the body’s immune system response to provide more accurate and faster diagnosis. Its scientific approach has been validated in over 20 independent cohorts involving over 1,000 patients and published in leading medical journals. The privately held, Burlingame, Calif.-based company is funded by Khosla Ventures, Stanford-StartX Fund and grants from the federal government. For more information, please visit www.inflammatix.comand follow the company on Twitter (@Inflammatix_Inc).

Media Contacts

For Inflammatix:
Tracy Morris
tracymorrispr@gmail.com
650-380-4413

Download PDF
February 15, 2018 – New Study Published in Nature Communications Suggests Sepsis Can Be Detected By Measuring the Immune System 2018-02-15T12:09:09+00:00

Bioinformatics Approach Forms the Basis of Inflammatix’s HostDx™ Sepsis Test

Burlingame, Calif., February 15, 2018 — Inflammatix announced findings from a new study published today in Nature Communications that suggest that diagnosing and determining who will likely develop sepsis can be improved with a data-driven approach that measures the immune system response to severe infection. A gene expression model used in the new study is a core component of HostDx™ Sepsis, a rapid molecular test that Inflammatix is developing to improve sepsis diagnosis. Sepsis, a dysregulated immune system response to infection, kills more than 250,000 Americans and costs the healthcare system more than $27 billion annually in the United States.

“Current tools for sepsis identification and triage are imprecise, which often results in patients being overtreated or undertreated and wastes significant healthcare resources. The findings in this new study suggest that measuring immune dysregulation could indicate infection severity and significantly improve sepsis diagnosis,” said Tim Sweeney, M.D., lead author of the new paper, and cofounder and chief executive officer of Inflammatix. “The technology used in this study forms the basis of our HostDx Sepsis test, which we plan to bring into hospitals and urgent care settings as a rapid test to help reduce the global burden of sepsis.”

The new study evaluated gene-based models designed to accurately predict 30-day mortality in patients with sepsis at the time of enrollment. The models were developed and evaluated on over 20 cohorts from clinical studies involving a wide range of populations and settings. Inflammatix holds exclusive license to a pending patent from Stanford University for the institution’s gene expression model from the new study.

The Stanford gene set licensed by Inflammatix, when combined with clinical severity scores (the current standard of care), demonstrated a substantial increase in prognostic power for 30-day mortality (i.e., an AUC increase of 9.8 percent, from 77 percent to 87 percent). This would translate to an ability to rule out approximately 20 percent more sepsis cases, compared to clinical severity scores alone. Such findings suggest this approach could help save substantial resources by avoiding unnecessary care.

“This new research, combined with previously published data, demonstrate the HostDx Sepsis test’s ability to identify the presence of bacterial and/or viral infection and determine the likelihood of a patient having or developing sepsis. We believe this powerful combination will strongly drive the economic value of HostDx Sepsis, a point we look forward to validating in interventional trials,” said Dr. Sweeney.

About the HostDx Sepsis Test

The HostDx Sepsis test helps diagnose sepsis by detecting the presence of a bacterial and/or viral infection and determining its severity. The test uses novel, validated technology to measure the expression levels of numerous host immune genes in blood samples and then applies proprietary algorithms to produce clinically actionable and timely results. The HostDx Sepsis test’s technology has been validated in 20 cohorts of over 1,000 patients, representing diverse populations and settings. The test has demonstrated a high sensitivity for organ dysfunction associated with sepsis (95 percent) and high negative predictive value (>98 percent).

About Inflammatix

Inflammatix is a molecular diagnostics company that is developing rapid tests that read the immune system, enabling improved patient care and reducing major public health burdens. The company’s initial focus is on acute bacterial and viral infections, and sepsis, where its HostDx™ tests will allow physicians to quickly get the right treatments to the right patients, reducing morbidity and mortality, health system costs, and antibiotic resistance. While current tests diagnose infections by “finding the bug” – an approach that misses the 70% of infections that never enter the bloodstream – Inflammatix evaluates the body’s immune system response to provide more accurate and faster diagnosis. Its scientific approach has been validated in over 20 independent cohorts involving over 1,000 patients and published in leading medical journals. The privately held, Burlingame, Calif.-based company is funded by Khosla Ventures, Stanford-StartX Fund and the U.S. government’s Defense Advanced Research Projects Agency (DARPA). For more information, please visit www.inflammatix.com and follow the company on Twitter (@Inflammatix_Inc).

Media Contacts

For Inflammatix:
Tracy Morris
tracymorrispr@gmail.com
650-380-4413

Download PDF
December 19, 2017 – Inflammatix Announces Appointment of Oliver Liesenfeld, M.D., as Chief Medical Officer 2018-02-15T12:10:17+00:00

BURLINGAME, Calif.Dec. 19, 2017 /PRNewswire/ — Inflammatix, a molecular diagnostics company that is developing rapid tests that read the immune system to improve disease diagnosis, today announced that Oliver Liesenfeld, M.D., has been appointed chief medical officer. Dr. Liesenfeld, a veteran of the diagnostics industry, comes to the company from Roche Molecular Diagnostics, where he served as chief medical officer since 2012.

Dr. Liesenfeld will oversee the clinical studies and regulatory approvals needed to commercialize Inflammatix’s HostDx™ tests, which will initially target acute infections and sepsis, respectively. These tests use the company’s novel, validated, bioinformatics-based approach of reading the genomic “fingerprint” of the host response to disease to quickly determine if a patient has a bacterial and/or viral infection – and thus, whether they need antibiotics – and to measure the severity of disease to determine if the patient is likely to have or develop sepsis.

“We are delighted to have an individual of Dr. Liesenfeld’s experience and stature join our team as we transform infectious disease diagnosis and resolve the pressing public health challenges of antibiotic resistance and sepsis,” said Tim Sweeney, M.D., Ph.D., cofounder and chief executive officer of Inflammatix. “With his extensive background in diagnostics, particularly in infectious diseases, and his broad regulatory experience, he will be key to helping us achieve our ambitious goals.”

Dr. Liesenfeld has over 25 years of industry and academic experience in the diagnostics field, with a focus on molecular diagnostics and infectious diseases. As chief medical officer at Roche Molecular Diagnostics, he built a state-of-the-art medical department and led the company’s clinical science, medical affairs, clinical operations and biometrics functions. His team designed and executed numerous clinical trials to support regulatory approvals and commercialization of the company’s broad product portfolio, including the LightCycler® SeptiFast test for use in sepsis diagnosis. Prior to Roche, Dr. Liesenfeld served as associate professor of Medical Microbiology and Infection Immunology at the Charite Medical School in Berlin, Germany, where his research focused on the immune response to infections. He holds an M.D. and a doctoral (Dr. med) degree from the Free University of Berlin, Germany and completed his residency in medical microbiology and infection epidemiology at the Charite Medical School, Berlin. He also completed a postdoctoral fellowship in the Division of Infectious Diseases and Geographic Medicine at Stanford University. Dr. Liesenfeld has authored more than 160 articles in peer-reviewed journals and more than 30 book chapters.

“I believe that a data-driven, bioinformatics approach that measures patients’ immune response represents the future of improved diagnosis for numerous diseases and conditions,” said Dr. Liesenfeld. “I am excited to join Inflammatix and advance their groundbreaking work in acute infections and sepsis, where current testing methods are inaccurate or too slow. I look forward to bringing their HostDx tests into the clinic where they can support the improved management of patients, helping physicians quickly get the right treatments to the right patients.”

About Inflammatix

Inflammatix is a molecular diagnostics company that is developing rapid tests that use bioinformatics and machine learning to read the immune system, enabling improved patient care and reducing major public health burdens. The company’s initial focus is on acute bacterial and viral infections, and sepsis, where its HostDx™ tests will allow physicians to quickly get the right treatments to the right patients, reducing morbidity and mortality, health system costs, and antibiotic resistance. While current tests diagnose infections by “finding the bug” – an approach that misses many infections because they never enter the bloodstream – Inflammatix evaluates the body’s immune system response to provide more accurate and faster diagnosis. Its scientific approach has been validated in 38 cohorts involving over 2,400 patients and published in leading medical journals. The privately held, Burlingame, Calif.-based company is funded by Khosla Ventures, Stanford-StartX Fund and the U.S. government’s Defense Advanced Research Projects Agency (DARPA). For more information, please visit www.inflammatix.com and follow the company on Twitter (@Inflammatix_Inc).

Media Contact:
Tracy Morris
tracymorrispr@gmail.com
650-380-4413

Download PDF

Logos

Horizontal format logos

Stacked format logos

Sign Up for updates: Find out the latest news.

STAY IN THE KNOW!